Merck
  • Home
  • Search Results
  • Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems.

Modification of Extracellular Vesicles by Fusion with Liposomes for the Design of Personalized Biogenic Drug Delivery Systems.

ACS nano (2018-07-06)
Max Piffoux, Amanda K A Silva, Claire Wilhelm, Florence Gazeau, David Tareste
ABSTRACT

Extracellular vesicles (EVs) are recognized as nature's own carriers to transport macromolecules throughout the body. Hijacking this endogenous communication system represents an attractive strategy for advanced drug delivery. However, efficient and reproducible loading of EVs with therapeutic or imaging agents still represents a bottleneck for their use as a drug delivery system. Here, we developed a method for modifying cell-derived EVs through their fusion with liposomes containing both membrane and soluble cargoes. The fusion of EVs with functionalized liposomes was triggered by polyethylene glycol (PEG) to create smart biosynthetic hybrid vectors. This versatile method proved to be efficient to enrich EVs with exogenous lipophilic or hydrophilic compounds, while preserving their intrinsic content and biological properties. Hybrid EVs improved cellular delivery efficiency of a chemotherapeutic compound by a factor of 3-4, as compared to the free drug or the drug-loaded liposome precursor. On one side, this method allows the biocamouflage of liposomes by enriching their lipid bilayer and inner compartment with biogenic molecules. On the other side, the proposed fusion strategy enables efficient EV loading, and the pharmaceutical development of EVs with adaptable activity and drug delivery property.

MATERIALS
Product Number
Brand
Product Description

Avanti
16:0-18:1 PC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, powder
Avanti
16:0-18:1 PC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
18:1 (Δ9-Cis) PE (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, chloroform solution
Avanti
18:1 (Δ9-Cis) PE (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, powder
Avanti
18:1 PEG2000 PE, Avanti Polar Lipids 880130C
Avanti
18:1 PEG2000 PE, Avanti Polar Lipids 880130P, powder
Sigma-Aldrich
L-α-Phosphatidylethanolamine, dioleoyl, ≥99% (GC), ≥98% (TLC), lyophilized powder
Sigma-Aldrich
1,2-Dioleoyl-sn-glycero-3-phosphocholine, lyophilized powder
Avanti
18:1 (Δ9-Cis) PC (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine, powder
Avanti
18:1 (Δ9-Cis) PC (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine, chloroform
Avanti
18:1 Liss Rhod PE, Avanti Polar Lipids 810150P, powder
Avanti
18:1-12:0 NBD PS, Avanti Polar Lipids 810195C
Avanti
18:1-12:0 NBD PS, Avanti Polar Lipids 810195P, powder
Avanti
18:1 Biotinyl Cap PE, Avanti Polar Lipids 870273C
Avanti
18:1 Biotinyl Cap PE, Avanti Polar Lipids 870273P, powder
Avanti
18:1 EPC (Cl Salt), Avanti Polar Lipids 890704C
Avanti
18:1 EPC (Cl Salt), Avanti Polar Lipids 890704P, powder
Avanti
18:1 PS (DOPS), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt), chloroform
Avanti
18:1 Liss Rhod PE, Avanti Polar Lipids 810150C
Avanti
18:1 PS (DOPS), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt), powder